|
||||||||||||
 |
||||||||||||
|
||||||||||||
Top Stories
Immunize.org Website and Clinical Resources
Featured Resources
Notable Publications
Upcoming Events
Watch and share the new 3-minute video introduction to Immunize.org and its resources
Immunize.org is delighted to share a new, 3-minute online video introducing our organization and the resources available on our website. The video is available now on our YouTube channel as the first in a new orientation series of quick 3-minute videos designed to help both new and experienced users become more familiar with our new website and get the most out of all the resources we offer. Each new orientation video will be featured in IZ Express as it is released. Horizontal versions of these videos, like this one, will orient viewers to the desktop format of the website; later vertical versions of the videos will feature the mobile format of the site. Immunize.org posts revised versions of four Chinese translations of VISs for varicella-containing vaccines
At the recommendation of an alert Chinese-speaking reader, Immunize.org requested the removal of Chinese characters included parenthetically in the document title of varicella-containing vaccine VISs as a synonym to the Chinese characters used throughout the document to refer to varicella or chickenpox. These parenthetical characters refer broadly to pox viruses and do not refer exclusively to “chickenpox.” To avoid any confusion, these characters in parentheses were removed from the titles. The VISs are dated August 6, 2021. MMRV (Measles, Mumps, Rubella, Varicella) Vaccine VIS To ensure you have the current translations, click on Vaccines & VISs at Immunize.org, then click on VISs, then select a specific vaccine. Scrolling down the resulting page, you will see the current English version, a list of current translations (i.e., corresponding to the current English VIS), and then, if applicable, a list of any out-of-date (yet best available) translations. Additional tips on using VISs appear at the bottom of the page.
FDA licenses Merck’s new 21-valent pneumococcal conjugate vaccine (PCV21) for adults; ACIP to consider recommendations for use this week
On June 17, FDA licensed Capvaxive (Merck), a 21-valent pneumococcal conjugate vaccine (PCV21), for use in adults age 18 years and older. This PCV21 targets several serotypes not included in other PCV brands that cause serious pneumococcal disease more often in adults than in children. It does not include certain serotypes in the PCV brands recommended for children.
O, Canada! Recognizing Canada’s 156th national anniversary on July 1, we are sharing select Canadian vaccination resources. Happy Canada Day to the vaccination providers and champions among our readers in Canada!
Advocacy groups:
Government links:
Should live vaccines be given to a healthy child whose mother is getting cancer chemotherapy? Watch the 3-minute answer, part of the Ask the Experts Video Series on YouTube. This week, our featured episode from the Ask the Experts Video Series addresses the question of whether to administer live virus vaccines to a household member of someone going through cancer chemotherapy. The video highlights the importance of vaccinating household contacts and other close contacts of people who are immunocompromised. Like, follow, and share Immunize.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise.
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
Spotlight on the website: Looking for a past IZ Express article? Here’s how to browse all issues.
This week, we focus on how to access any of the 1,762 past issues of IZ Express (known from 1997 through 2022 as IAC Express). Association of Immunization Managers shares six new e-learning modules for vaccinators and community vaccine champions, with updated guide, Connecting the Dots: Vaccine Confidence
The Association of Immunization Managers (AIM) iREACH team created a series of six e-learning modules to help support anyone who engages in community conversations about influenza, COVID-19, and vaccine safety. These free modules also address racial and ethnic disparities in vaccine coverage and disease outcomes and how to close these gaps.
View the modules. "Effects of HPV Vaccination on the Development of HPV-Related Cancers: A Retrospective Analysis of a United States-Based Cohort." published in Journal of Clinical Oncology
In the May 29 issue, Journal of Clinical Oncology published a meeting abstract Effects of HPV Vaccination on the Development of HPV-Related Cancers: A Retrospective Analysis of a United States-Based Cohort. This study linked vaccination data and cancer diagnosis data for patients age 9–39 years. Patients vaccinated or unvaccinated for HPV were compared.
These results add to the evidence of HPV vaccine’s real world effectiveness in preventing several types of cancer and precancerous changes caused by HPV. Today: Virtual: Watch June 26–28 ACIP meeting with wide-ranging discussion on vaccine preventable diseases
CDC convenes its ACIP June 26–28, starting at 8:00 a.m. (ET). ACIP will discuss vaccines to prevent chikungunya, dengue, COVID-19, influenza, pneumococcal, meningococcal, RSV, and HPV. Anticipated votes are expected to have an impact on the practices of many vaccination providers.
In-person: Registration open for CDC’s 49th National Immunization Conference on August 12–14 in Atlanta; CE credit offered
CDC will host National Immunization Conference 2024 on August 12–14 in Atlanta, GA. Program content will cover science, policy, education, and implementation issues related to immunization and vaccine-preventable diseases. Virtual: CDC hosts COCA call "Mpox Update: Clinical Management and Outbreaks" on June 27 at 2:00 p.m. (ET); CE credit offered
CDC will host a Clinician Outreach and Communication Activity (COCA) call titled Mpox Update: Clinical Management and Outbreaks, 2:00–3:00 p.m. (ET) on June 27. During this COCA call, presenters will give updates on the mpox clade I outbreak in the Democratic Republic of the Congo (DRC) and remind clinicians to be alert for mpox in patients with recent travel to the DRC. Discussion will address when to suspect a case of mpox, clinical management and prevention of clade II mpox, and recent mpox vaccination data. |
||||||||||||
|
